Armata Pharmaceuticals (ARMP) Non-Current Deferred Tax Liability (2013 - 2026)

Armata Pharmaceuticals has disclosed Non-Current Deferred Tax Liability across 14 years of filings, most recently posting $3.1 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $3.1 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (changed 0.0% YoY), and the FY2025 annual result was $3.1 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability came in at $3.1 million for Q1 2026 at Armata Pharmaceuticals, roughly flat from $3.1 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.1 million in Q1 2022 to a low of $3.1 million in Q1 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $3.1 million (2022), against an average of $3.1 million.
• Peak annual rise in Non-Current Deferred Tax Liability reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Armata Pharmaceuticals' Non-Current Deferred Tax Liability stood at $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024, then changed by 0.0% to $3.1 million in 2025, then changed by 0.0% to $3.1 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $3.1 million (Q1 2026), $3.1 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.